Drugs / GZR33
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07242664 | Oct 2025 → Feb 2026 overdue | type 1 diabetes mellitus | Gan and Lee Pharmaceuticals, USA | Recruiting | No outcome recorded |
| Phase 1 | NCT06556641 | Dec 2022 → Feb 2023 | — | Gan and Lee Pharmaceuticals, USA | Completed | No outcome recorded |
| Phase 1 | NCT06548932 | Jun 2022 → Feb 2023 | — | Gan and Lee Pharmaceuticals, USA | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06558708 | Jun → Dec 2024 overdue | type 2 diabetes mellitus | Gan and Lee Pharmaceuticals, USA | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07527078 | Apr 2026 overdue | type 2 diabetes mellitus | Gan & Lee Pharmaceuticals. | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07387003 Comparator | Apr 2026 → Feb 2027 expected | type 2 diabetes mellitus | Gan & Lee Pharmaceuticals. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GZR33 | “This trial intends to investigate the pharmacodynamics, pharmacokinetics, safety, and tolerability of insulin GZR33 (hereafter referred to as GZR33) and estimate its potency in...” NCT07242664 ↗ |
| Route | Subcutaneous | “Participants will receive GZR33 Injection or placebo, s.c. a single dose (Part A)” NCT06548932 ↗ |